76P - Adjuvant chemotherapy in resected NSCLC: treatment factors that impact survival outcomes

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Early Stage
Presenter Katherine Ramsden
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors K. Ramsden, J. Laskin, C. Ho
  • Medical Oncology, British Columbia Cancer Agency, V5Z4E6 - Vancouver/CA


Platinum-based adjuvant chemotherapy is the standard of care for resected stage II non-small cell lung cancer (NSCLC). In practice, the proportion of patients who receive adjuvant treatment is limited and the dose delivered is often reduced compared to the clinical trials. The purpose of this population-based study was to identify factors that predict for receiving adjuvant therapy and assess the impact of delayed administration and dose reduction on survival.